Literature DB >> 32858565

The Use of NACSELD and EASL-CLIF Classification Systems of ACLF in the Prediction of Prognosis in Hospitalized Patients With Cirrhosis.

Zhujun Cao1, Yuhan Liu1, Minghao Cai1, Yumin Xu1, Xiaogang Xiang1, Gangde Zhao1,2, Wei Cai1, Hui Wang1, Weijing Wang1,2, Qing Xie1,2.   

Abstract

INTRODUCTION: Acute-on-chronic liver failure (ACLF) is defined by the European Association for the Study of the Liver-Chronic Liver Failure (EASL-CLIF) consortium and the North American Consortium for the Study of End-Stage Liver Disease (NACSELD) as an acute deterioration of cirrhosis with multiple organ failures and high short-term mortality. However, their diagnostic criteria differ. We aimed to compare these 2 criteria in the prediction of prognosis in hospitalized cirrhosis.
METHODS: This was a prospective study of nonelectively hospitalized patients with cirrhosis (N = 468) from a single tertiary hospital between 2016 and 2018. Baseline characteristics, incidence, and types of organ failure and survival data at 7, 28, and 90 days were collected. Prognostic utilities of the 2 criteria were compared.
RESULTS: One hundred thirty-seven of 468 patients (29.3%) had EASL-CLIF ACLF, and 35 of 468 (7.4%) had NACSELD ACLF. The 28-day transplant-free survival of ACLF was 58.4% using EASL-CLIF and 37.1% using the NACSELD criteria. In predicting 28-day mortality, the NACSELD criteria demonstrated significantly higher overall accuracy (92.0% vs 85.3%, P < 0.01), specificity (99.7% vs 84.0%, P < 0.001), and positive predictive value (97.1% vs 50.4%, P < 0.001) but lower sensitivity (49.3% vs 92.5%, P < 0.001) and negative predictive value (91.6% vs 98.5%, P < 0.001) than those of EASL-CLIF. The results were similar in predicting 7-day outcome. However, the overall accuracy became similar between NACSELD and EASL-CLIF ACLF criteria in predicting 90-day mortality (86.3% vs 88.7%, P = 0.27) because of the decrease of sensitivity and negative predictive value of NACSELD ACLF criteria. The prognostic performance of these 2 ACLF criteria was similar when applied to patients with or without hepatitis B virus infection as an etiology of cirrhosis. DISCUSSION: There are both caveats and utilities of NACSELD and EASL-CLIF ACLF criteria in prognosis prediction in patients with cirrhosis. NACSED criteria is highly accurate in predicting morality, whereas the EASL-CLIF criteria is more sensitive to identify patients who would benefit from liver transplantation.

Entities:  

Year:  2020        PMID: 32858565     DOI: 10.14309/ajg.0000000000000771

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  5 in total

Review 1.  Alcohol and Acute-on-Chronic Liver Failure.

Authors:  Maria Pilar Ballester; Richard Sittner; Rajiv Jalan
Journal:  J Clin Exp Hepatol       Date:  2021-12-22

Review 2.  Definition and classification of acute-on-chronic liver diseases.

Authors:  Yuan-Yao Zhang; Zhong-Ji Meng
Journal:  World J Clin Cases       Date:  2022-05-26       Impact factor: 1.534

3.  COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status.

Authors:  Zhujun Cao; Chenxi Zhang; Shuang Zhao; Zike Sheng; Xiaogang Xiang; Ruokun Li; Zhuping Qian; Yinling Wang; Bin Chen; Ziqiang Li; Yuhan Liu; Baoyan An; Huijuan Zhou; Wei Cai; Hui Wang; Honglian Gui; Haiguang Xin; Qing Xie
Journal:  Infect Dis Poverty       Date:  2022-05-16       Impact factor: 10.485

4.  Transplantation for EASL-CLIF and APASL acute-on-chronic liver failure (ACLF) patients: The TEA cohort to evaluate long-term post-Transplant outcomes.

Authors:  Lei Xia; Zi-Yun Qiao; Zi-Jie Zhang; Zi-Cheng Lv; Huan Tong; Ying Tong; Hao-Xiang Wu; Xiao-Song Chen; Han-Yong Sun; Jian-Jun Zhang; Wolfgang Ervin Thasler; Hao Feng; Qiang Xia
Journal:  EClinicalMedicine       Date:  2022-06-04

5.  Characteristics and risk factors of infections in patients with HBV-related acute-on-chronic liver failure: a retrospective study.

Authors:  Qian Zhang; Baoxian Shi; Liang Wu
Journal:  PeerJ       Date:  2022-07-05       Impact factor: 3.061

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.